Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 60

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
 
     4,051,368  
     4,747,009  
     (695,641) 
     (14.7)%

    Total operating expenses 
     9,029,322  
     8,052,124  
     977,198  
     12.1%

    Loss from operations 
     (9,029,322) 
     (8,052,124) 
     (997,198) 
     12.1%

    Other income, net 
     55,676  
     230,180  
     (174,504) 
     (75.8)%
  
    Change in fair value of convertible promissory notes 
     (787,703) 
     -  
     (787,703) 
     - 

    Net loss 
    $(9,761,349) 
    $(7,821,944) 
    $(1,939,405) 
     24.8%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(18.09) 
    $(25.79) 
    $7.70  
     (29.9)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     539,538  
     303,336  

Research
and Development Expenses

Research
and development expenses were approximately $5.0 million for the six months ended June 30, 2025, compared to approximately $3.3
million for the six months ended June 30, 2024, representing an increase of approximately $1.7 million, or 50.6%. The increase was
primarily driven by higher clinical trial costs of approximately $2.3 million related to our ongoing Phase 1 study. This increase
was partially offset by a decrease of approximately $0.6 million in payroll and related expenses.

General
and Administrative Expenses

General
and administrative expenses were approximately $4.0 million for the six months ended June 30, 2025, compared to approximately $4.7
million for the six months ended June 30, 2024, representing a decrease of approximately $0.7 million, or 14.7%. The decrease was
primarily attributable to a reduction of approximately $1.5 million in stock-based compensation